Rafarma commences antibiotic Ceftriaxone production
Produced in Unit 2 of Rafarma’s Terbuni plant, Ceftriaxone formulated for injections will be packed in 10ml bottles with single gram dosages. With an estimated Ceftriaxone market of
Ionis Pharmaceuticals has entered a licence agreement granting global pharmaceutical company Recordati exclusive rights to develop and commercialise zilganersen to treat Alexander disease (AxD) in countries outside the US.
The findings showed that small inhaled doses yielding high peak, short duration lung pirfenidone concentrations provide statistically greater anti-fibrotic efficacy than higher oral doses resulting in low peak